STOCK MARKETS

Windward Bio raises $251.2M in IPO on Nasdaq

By Investing.com1 min readInvesting.com
Windward Bio raises $251.2M in IPO on NasdaqWindward Bio raises $251.2M in IPO on Nasdaq

Windward Bio Group AG (Nasdaq: WWB), a clinical-stage biotechnology company based in Basel, Switzerland, closed its initial public offering, raising approximately $251.2 million in gross proceeds, including a concurrent private placement.

The IPO consisted of 11,838,234 common shares priced at $17.00 per share, including the full exercise of the underwriters’ option to purchase an additional 1,544,117 shares. Windward’s shares began trading on the Nasdaq Global Select Market on Nov. 13, 2026.

Alongside the IPO, Windward closed a concurrent private placement to Sanofi Foreign Participations B.V., comprising 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, both at the IPO price, for an aggregate purchase price of $50.0 million. Those shares and warrants were not registered under the Securities Act of 1933.

Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank served as joint book-running managers for the offering.

Windward is developing antibody medicines for respiratory and dermatologic conditions, including asthma, chronic obstructive pulmonary disease, and atopic dermatitis. Its lead candidate, WIN378, is being evaluated in Phase 2/3 and Phase 2 clinical studies. A second candidate, WIN027, is in a Phase 1 healthy volunteer study.